Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A metabolomic signature study with sound observational design, clear discriminatory performance (AUC 0.78), and mechanistic pathway findings, but based on cross-sectional association in a single population requiring validation before clinical use.
A narrative review synthesizing current evidence and guidelines on MASLD/MASH epidemiology, associations, and management recommendations for clinical practice.
Cross-sectional study demonstrating clear associations between CMI and hepatic enzymes and metabolic markers in overweight/obese adults, but limited by observational design and inability to establish causation.
Single-arm, uncontrolled pilot study with small sample size (n=30) and surrogate proteomic endpoints; demonstrates feasibility of proteomics in LCD response but lacks comparator group and hard clinical outcomes.
A narrative review synthesizing pathogenic mechanisms and clinical relationships of MASLD with metabolic syndrome, offering conceptual framework rather than new empirical evidence.
World Journal of Pharmacy and Pharmaceutical Sciences
Small single-centre animal study with surrogate biochemical endpoints and no clinical outcome; results are promising but require human validation before clinical application.
World Journal of Pharmacy and Pharmaceutical Sciences
Small animal study (n=20 rats) with surrogate biochemical endpoints and no human translation; demonstrates proof-of-concept but lacks the design and population scope needed to guide clinical practice.
A sound single-centre animal study with multiple relevant endpoints showing metabolic benefit, but limited to mice and surrogate markers; results require confirmation in humans.